Business Wire

Biggest Edition of China Hi-Tech Fair (CHTF) Concludes in Shenzhen, China

Share

The 24th and the biggest edition of China Hi-Tech Fair (CHTF) just concluded on November 19, 2022 in Shenzhen, China. With an exhibition area of 406,000 square meters, the 5-day event showcased 8,667 items from 5,671 exhibitors, covering AI, intelligent driving, digital economy, 5G, Internet of Things, anti-epidemic technology solutions, chip technology, big data, information security, blockchain etc, and gathered 214,000 visitors from 28 countries and regions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005333/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Biggest Edition of China Hi-Tech Fair (CHTF) Concludes in Shenzhen, China (Graphic: Business Wire)

As a reputed exhibition and trade platform, CHTF has a great appeal for Chinese companies and global companies alike, including the world's leading technology companies such as Huawei, ZTE, Iflytek, Honeywell, BASF and FUJI, as well as startups and technologically advanced companies. This year, CHTF attracted 41 countries/international organizations, 29 overseas government delegations, and 498 overseas exhibitors such as Germany's SRT Resistor Technology and Austria's Usound Audio.

"First-time" and "debut" were the buzzwords at CHTF 2022. This year, for the first time Water Conservation and Innovation Exhibition was launched to showcase advanced water-saving concepts and technologies; for the first time the exhibition for leading SMEs that specialize in niche sectors was set up, which gathered 43 companies to display innovations in AI and unmanned aerial vehicles. Meanwhile, 1,302 high-tech products and 407 new technologies were debuted at CHTF 2022.

On the sidelines of the exhibition, 148 forums and symposiums were held, including China Hi-Tech Forum 2022 focused on world-changing new technologies, and CHTF Belt & Road Initiative Cooperation Forum exploring the digital mode of the Belt & Road Initiative.

In the meantime, over 300 one-on-one business matching talks provided perfect business opportunities for entrepreneurs, investors and professional buyers, connecting 265 projects with over 50 potential investors. "Makers’ Night", another business matching activity, attracted nearly 60 investment institutions and more than 300,000 online viewers.

Having been continuously pursuing quality and influence over the past 22 years, CHTF has become an influential high-tech fair and an important cooperation platform in the high-tech industry and aims to unite as many innovation forces as possible to empower the economic, society and the industrial development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For exhibitor and visitor
Ms. XIE Yan, +8675582848652, selenaxie@chtf.com
Ms. WANG Peggie, +8675582848962, wangyq@chtf.com
Ms. CUI Can, +8675582848764, cathy_cui@chtf.com
Ms. YANG Dan, +86 755 8284 8695, yangd@chtf.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Announces Grant of Employment Inducement Awards1.3.2024 22:15:00 CET | Press release

IFF (NYSE: IFF) today announced the grant of employment inducement awards to J. Erik Fyrwald, IFF Chief Executive Officer and member of the Board of Directors. The Company's Board of Directors approved the employment inducement awards on Jan. 9, 2024, with a grant date of March 1, 2024, as a material inducement to enter into an offer of employment in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08 that requires shareholder approval of equity-based compensation plans. Listing Rule 303A.08 requires the public announcement of such an award. The inducement awards will consist of (i) a target award of 68,750 performance share units (with a maximum award of 171,875 performance share units), subject to meeting the applicable performance targets set forth in the award agreement, and (ii) 56,250 restricted stock units, 100% of which will vest on the three-year anniversary of the grant date, for a maximum potential combined payout of 228,125

Whitehorse Liquidity Partners Recognized by Private Equity International’s 2023 Awards1.3.2024 16:30:00 CET | Press release

Whitehorse Liquidity Partners (together with its advisory affiliates, “Whitehorse”), a specialized investment manager focused on providing structured liquidity solutions to the alternative asset class, is pleased to announce recognition from Private Equity International (PEI) in the 2023 PEI Awards. Whitehorse placed third in the Secondaries Firm of the Year in the Americas category alongside Blackstone Strategic Partners and HarbourVest Partners and was voted Firm of the Year in Canada. “We are honoured to have been recognized again in two categories by the PEI Awards,” said Yann Robard, Managing Partner of Whitehorse. “For the fourth time among the top three Secondaries Firm of the Year in the Americas category (2018, 2020, 2022 and 2023) and the sixth time among the top three in the Firm of the Year in Canada category (2017, 2018, 2020, 2021, 2022 and 2023). You often hear us say that big is beautiful, growth is good and scale matters. Our scale has enabled us, not disrupted us. We

Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign1.3.2024 14:30:00 CET | Press release

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin KleinETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITYfragrance portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/ Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire) Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnerin

Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV1.3.2024 13:35:00 CET | Press release

The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/ Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire) With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprie

GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta1.3.2024 09:37:00 CET | Press release

GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy o

HiddenA line styled icon from Orion Icon Library.Eye